ACLX Arcellx
- 49.770
- +0.030+0.06%
- 49.770
- 0.0000.00%
Arcellx News
Arcellx Is Maintained at Buy by HC Wainwright & Co.
Arcellx Is Maintained at Buy by HC Wainwright & Co.
Arcellx Price Target Cut to $80.00/Share From $82.00 by HC Wainwright & Co.
Arcellx Price Target Cut to $80.00/Share From $82.00 by HC Wainwright & Co.
HC Wainwright & Co. Maintains Buy on Arcellx, Lowers Price Target to $80
HC Wainwright & Co. analyst Emily Bodnar maintains Arcellx (NASDAQ:ACLX) with a Buy and lowers the price target from $82 to $80.
Buy Rating Affirmed for Arcellx Inc. Amidst Promising Trial Progress and Strategic Partnerships
Arcellx, Inc. (NASDAQ:ACLX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
Arcellx, Inc. (NASDAQ:ACLX) just released its quarterly report and things are looking bullish. The results were impressive, with revenues of US$39m exceeding analyst forecasts by 90%, and statuto
Arcellx First Quarter 2024 Earnings: Beats Expectations
Needham: Reiterates Arcellx (ACLX.US) rating and adjusted from buy to buy rating, target price is $81.00.
Needham: Reiterates Arcellx (ACLX.US) rating and adjusted from buy to buy rating, target price is $81.00.
Needham Reiterates Buy on Arcellx, Maintains $81 Price Target
Needham analyst Gil Blum reiterates Arcellx (NASDAQ:ACLX) with a Buy and maintains $81 price target.
Arcellx Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/10/2024 64.42% Needham → $81 Reiterates Buy → Buy 05/07/2024 64.42% Needham → $81 Reiterates Buy → Buy
Arcellx Inc (ACLX) Q1 2024 Earnings: Narrower Losses and Revenue Surge
Arcellx Shares Are Trading Lower After the Company Reported Q1 Financial Results.
Arcellx Shares Are Trading Lower After the Company Reported Q1 Financial Results.
Buy Rating Affirmed for Arcellx Inc on Robust IMMagine-3 Study Prospects and Efficient Manufacturing
Buy Rating Justified for Arcellx Inc. Amidst Progress in Anito-cel's Clinical Development and Regulatory Milestones
Barclays Reaffirms Their Buy Rating on Arcellx Inc (ACLX)
Kite and Arcellx Prepare to Launch Phase III Multiple Myeloma Trial
Buy Rating for Arcellx Inc: Strategic Positioning and Promising Clinical Trials Fuel Positive Outlook
Gilead's Kite, Arcellx Share Phase 3 Trial Design for CAR-T Multiple Myeloma Asset
Arcellx Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results.
Arcellx Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results.
Arcellx Q1 EPS $(0.14) Beats $(0.51) Estimate, Sales $39.26M Beat $20.67M Estimate
Arcellx (NASDAQ:ACLX) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.51) by 72.55 percent. This is a 75.86 percent increase over losses of $(0.58) per
Arcellx | 10-Q: Quarterly report
Analysis
Price Target
No Data
